Linagliptin approved for type 2 diabetes.
نویسنده
چکیده
منابع مشابه
Linagliptin: The Game Changer in Type 2 Diabetes Mellitus
The rate of occurring of Type 2 diabetes mellitus have been proportionally increased with respect to time in the last 50 years. Multiple therapies are required by the type 2 diabetes patients r proper treatment of hyperglycaemic condition Linagliptin is the latest approved oral hypoglycaemic agent which act by inhibition of DPP-4 (Dipeptidyl peptidase-4) enzyme. On 2 May 2011, USFDA approved Li...
متن کاملEmpagliflozin/linagliptin single‐tablet combination: first‐in‐class treatment option
BACKGROUND The availability of a dual sodium glucose co-transporter 2/dipeptidyl peptidase-4 inhibitor combination in a single-tablet combination (STC) represents a new therapeutic option for patients with type 2 diabetes. Empagliflozin/linagliptin STC has been recently approved by the US Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM). AIM The aim of this st...
متن کاملLinagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
Incretin based therapies have been introduced into the treatment options of type 2 diabetes a few years ago. Among them, the orally active DPP-4 inhibitors have established themselves as insulinotropic agents. Their advantage is the glucose-dependent insulinotropic action without an intrinsic risk for causing hypoglycemia. Additionally DPP-4 inhibitors have a glucose dependent glucagonostatic a...
متن کاملClinical Medicine Insights: Endocrinology and Diabetes Combination of Linagliptin and Metformin for the Treatment of Patients with Type 2 Diabetes
ABSTR ACT: Type 2 diabetes mellitus (T2DM) is a progressive condition requiring long-term treatment. Most patients with T2DM are unable to maintain normoglycemia using metformin alone; thus, combination therapy is a pivotal part of disease management. Addition of the dipeptidyl peptidase-4 inhibitor linagliptin, with its proven efficacy, low propensity for hypoglycemia, and weight neutrality, h...
متن کاملCombination of Linagliptin and Metformin for the Treatment of Patients with Type 2 Diabetes
Type 2 diabetes mellitus (T2DM) is a progressive condition requiring long-term treatment. Most patients with T2DM are unable to maintain normoglycemia using metformin alone; thus, combination therapy is a pivotal part of disease management. Addition of the dipeptidyl peptidase-4 inhibitor linagliptin, with its proven efficacy, low propensity for hypoglycemia, and weight neutrality, has been sho...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
دوره 68 12 شماره
صفحات -
تاریخ انتشار 2011